Taysha Gene Therapies Cash on Hand 2020-2023 | TSHA
Taysha Gene Therapies cash on hand from 2020 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Taysha Gene Therapies Annual Cash on Hand
(Millions of US $) |
| 2023 |
$144 |
| 2022 |
$88 |
| 2021 |
$149 |
| 2020 |
$251 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Cash on Hand
(Millions of US $) |
| 2023-12-31 |
$144 |
| 2023-09-30 |
$164 |
| 2023-06-30 |
$45 |
| 2023-03-31 |
$63 |
| 2022-12-31 |
$88 |
| 2022-09-30 |
$34 |
| 2022-06-30 |
$66 |
| 2022-03-31 |
$97 |
| 2021-12-31 |
$149 |
| 2021-09-30 |
$189 |
| 2021-06-30 |
$197 |
| 2021-03-31 |
$229 |
| 2020-12-31 |
$251 |
| 2020-09-30 |
$279 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.454B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
